yashraj 产品代理
yashraj 产品代理
我们鼓励和促进新知识的创造、发现、传播和应用，并促进学术联盟。我们已经进入诱导多能干细胞衍生疾病特异性模型领域，用于高通量药物筛选和毒理学测试。已经建立了一个从临床癌症患者中提取人类临床标本的生物库，以分离其细胞衍生物（原发癌细胞、血液来源的iPSC、iPSC来源的分化心肌细胞和肝细胞）。通过这个项目，我们计划为新药的发现做出贡献；为病人提供个性化医疗；以及干细胞和组织库。
YBL的研发工作得到了印度政府科技部科学和工业研究司的批准。
Native
Inflammatory Markers
Cancer Markers
Infection Markers
Renal Markers
Veterinary Markers
Other Markers
Recombinant
Inflammatory Markers
Cardiac Markers
Renal Markers
Infection Markers
Other Markers
Antibodies
Monoclonal Antibodies
Stem Cell
Antibody Phage Display
The products manufactured by YBL encompass a whole range of disease markers, including infectious diseases, various cancers, cardiac, renal, liver, neurological and autoimmune disorders. YBL has developed more than fifty high pure native antigens, sourced from various human biological fluids, including CRP, CA15-3, CA125, CA19-9, CA72-4, HBsAg-Ad and HBsAg-Ay, AIM etc in close collaboration with the diagnostic companies. With an emphasis on long term stability and specificity, our antigens are tested in multiple platforms for quality by Immunonephelometry, Immunoturbidimetry, Latex Agglutination, ECLIA and ELISA to ensure batch to batch consistency and by PCR and US-FDA approved CLIA for compliance and safety.
We encourage and facilitate the creation, discovery, dissemination and application of new knowledge and foster academic alliances. We have entered in the area of induced pluripotent stem cell-derived disease specific models for high-throughput drug screening and toxicology testing. A bio-repository of human clinical specimens from patients with broad clinical categories of cancer has been established to isolate their cellular derivatives (primary cancer cells, blood-derived iPSCs, iPSC-derived differentiated cardiomyocytes and hepatocytes).Through this program we plan to contribute to new drug discovery; personalized medicine for patients; and stem cell and tissue banking.
Research and Development (R&D) work at YBL is approved by the Department of Science and Industrial Research, Ministry of Science and Technology, Government of India.
